阿那白滞素治疗急性痛风的有效性：初始治疗与难治性治疗的回顾性分析 - Suppr

Suppr

超能文献

Effectiveness of Anakinra in Acute Gout: A Retrospective Review of Initial and Refractory Therapy.

作者信息

Petite Sarah E

机构信息

University of Toledo College of Pharmacy, Toledo, OH.

出版信息

Am J Ther. 2017 Sep/Oct;24(5):e633-e634. doi: 10.1097/MJT.0000000000000524.

DOI:10.1097/MJT.0000000000000524

PMID:27763889

Abstract

摘要

相似文献

Effectiveness of Anakinra in Acute Gout: A Retrospective Review of Initial and Refractory Therapy.

Am J Ther. 2017 Sep/Oct;24(5):e633-e634. doi: 10.1097/MJT.0000000000000524.

IL1 inhibition in gout-where are we a decade on?

Arthritis Res Ther. 2019 Nov 11;21(1):233. doi: 10.1186/s13075-019-2027-3.

Interleukin-1 inhibition by anakinra in refractory chronic tophaceous gout.

Int J Rheum Dis. 2011 Aug;14(3):e33-7. doi: 10.1111/j.1756-185X.2011.01629.x.

Anakinra suppresses familial Mediterranean fever crises in a colchicine-resistant patient.

Neth J Med. 2008 Dec;66(11):489-91.

Anakinra's efficacy is variable in refractory gout: report of ten cases.

Semin Arthritis Rheum. 2010 Dec;40(3):210-4. doi: 10.1016/j.semarthrit.2010.03.001. Epub 2010 May 21.

The efficacy of anakinra in an adolescent with colchicine-resistant familial Mediterranean fever.

Eur J Pediatr. 2008 Jun;167(6):695-6. doi: 10.1007/s00431-007-0547-3. Epub 2007 Jun 23.

IL-1 inhibition with anakinra in a patient with refractory gout.

J Clin Rheumatol. 2009 Oct;15(7):366. doi: 10.1097/RHU.0b013e3181be2423.

Treatment of acute gout.

Rheum Dis Clin North Am. 2014 May;40(2):329-41. doi: 10.1016/j.rdc.2014.01.008. Epub 2014 Feb 19.

Anakinra treatment in patients with gout and type 2 diabetes.

Clin Rheumatol. 2015 May;34(5):981-4. doi: 10.1007/s10067-014-2601-7. Epub 2014 Apr 15.

Case of anakinra as a steroid-sparing agent for gout inflammation.

Arthritis Rheum. 2009 Sep 15;61(9):1268-70. doi: 10.1002/art.24694.

引用本文的文献

Get OUT: Factors Associated With a Longer Length of Stay in Patients Admitted With an Acute Gout Flare, and the Effects of Anakinra on Length of Stay.

Int J Rheum Dis. 2025 Sep;28(9):e70418. doi: 10.1111/1756-185x.70418.

A single-centre retrospective case series of Anakinra for incident calcium pyrophosphate deposition disease.

Clin Rheumatol. 2023 Jul;42(7):1833-1837. doi: 10.1007/s10067-023-06573-0. Epub 2023 Mar 13.

Effectiveness and safety of anakinra in gouty arthritis: A case series and review of the literature.

Front Med (Lausanne). 2023 Jan 12;9:1089993. doi: 10.3389/fmed.2022.1089993. eCollection 2022.

Human recombinant interleukin-38 suppresses inflammation in mouse models of local and systemic disease.

Cytokine. 2021 Jan;137:155334. doi: 10.1016/j.cyto.2020.155334. Epub 2020 Oct 28.

Managing Gout in the Patient with Renal Impairment.

Drugs Aging. 2018 Apr;35(4):263-273. doi: 10.1007/s40266-018-0517-7.

What makes gouty inflammation so variable?

BMC Med. 2017 Aug 18;15(1):158. doi: 10.1186/s12916-017-0922-5.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

相似文献

Effectiveness of Anakinra in Acute Gout: A Retrospective Review of Initial and Refractory Therapy.

Am J Ther. 2017 Sep/Oct;24(5):e633-e634. doi: 10.1097/MJT.0000000000000524.

IL1 inhibition in gout-where are we a decade on?

Arthritis Res Ther. 2019 Nov 11;21(1):233. doi: 10.1186/s13075-019-2027-3.

Interleukin-1 inhibition by anakinra in refractory chronic tophaceous gout.

Int J Rheum Dis. 2011 Aug;14(3):e33-7. doi: 10.1111/j.1756-185X.2011.01629.x.

Anakinra suppresses familial Mediterranean fever crises in a colchicine-resistant patient.

Neth J Med. 2008 Dec;66(11):489-91.

Anakinra's efficacy is variable in refractory gout: report of ten cases.

Semin Arthritis Rheum. 2010 Dec;40(3):210-4. doi: 10.1016/j.semarthrit.2010.03.001. Epub 2010 May 21.

The efficacy of anakinra in an adolescent with colchicine-resistant familial Mediterranean fever.

Eur J Pediatr. 2008 Jun;167(6):695-6. doi: 10.1007/s00431-007-0547-3. Epub 2007 Jun 23.

IL-1 inhibition with anakinra in a patient with refractory gout.

J Clin Rheumatol. 2009 Oct;15(7):366. doi: 10.1097/RHU.0b013e3181be2423.

Treatment of acute gout.

Rheum Dis Clin North Am. 2014 May;40(2):329-41. doi: 10.1016/j.rdc.2014.01.008. Epub 2014 Feb 19.

Anakinra treatment in patients with gout and type 2 diabetes.

Clin Rheumatol. 2015 May;34(5):981-4. doi: 10.1007/s10067-014-2601-7. Epub 2014 Apr 15.

Case of anakinra as a steroid-sparing agent for gout inflammation.

Arthritis Rheum. 2009 Sep 15;61(9):1268-70. doi: 10.1002/art.24694.

引用本文的文献

Get OUT: Factors Associated With a Longer Length of Stay in Patients Admitted With an Acute Gout Flare, and the Effects of Anakinra on Length of Stay.

Int J Rheum Dis. 2025 Sep;28(9):e70418. doi: 10.1111/1756-185x.70418.

A single-centre retrospective case series of Anakinra for incident calcium pyrophosphate deposition disease.

Clin Rheumatol. 2023 Jul;42(7):1833-1837. doi: 10.1007/s10067-023-06573-0. Epub 2023 Mar 13.

Effectiveness and safety of anakinra in gouty arthritis: A case series and review of the literature.

Front Med (Lausanne). 2023 Jan 12;9:1089993. doi: 10.3389/fmed.2022.1089993. eCollection 2022.

Human recombinant interleukin-38 suppresses inflammation in mouse models of local and systemic disease.

Cytokine. 2021 Jan;137:155334. doi: 10.1016/j.cyto.2020.155334. Epub 2020 Oct 28.

Managing Gout in the Patient with Renal Impairment.

Drugs Aging. 2018 Apr;35(4):263-273. doi: 10.1007/s40266-018-0517-7.

What makes gouty inflammation so variable?

BMC Med. 2017 Aug 18;15(1):158. doi: 10.1186/s12916-017-0922-5.